# US 2015/0148302 A1 · Peptide Inhibitors of Caspase 2 Activation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148302 A1
- Document ID: US20150148302A1
- Status: Published application
- Kind: A1
- Application number: 14/201,132
- Filed: 2014-03-07
- Published: 2015-05-28
- Earliest claimed: 2011-09-09
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: The Trustees of Columbia University in the city of New York
- Inventors: Carol M. Troy
- Web page: https://patentgrep.com/patent/US20150148302A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to compositions, including membrane permeable complexes, comprising a Caspase 2 activation inhibitory peptide having the amino acid sequence AFDAFC as well as methods of using the same for the treatment of neurodegenerative conditions associated with apoptosis in the central nervous system, such as Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's chorea, and Creutzfeld-Jacob disease.

## Claims

### Claim 1

A Caspase 2 activation inhibitor composition comprising the amino acid sequence AFDAFC.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the amino acid sequence AFDAFC is conjugated to a cell-penetrating peptide.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the cell-penetrating peptide is selected from the group consisting of Pen1, transportan, pIS1, Tat(48-60), pVEC, MAP, and MTS.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the cell-penetrating peptide is Peril.

### Claim 5

A method of treating neurodegenerative conditions comprising administering, intranasally, an effective amount of a Caspase 2 activation inhibitor composition comprising the amino acid sequence AFDAFC to a subject in need thereof, wherein the neurodegenerative conditions is treated by such administration.

### Claim 6 (depends on 5)

The method of claim 5, wherein the Caspase 2 activation inhibitor composition comprising the amino acid sequence AFDAFC is conjugated to a cell-penetrating peptide.

### Claim 7

A method of inhibiting a neurodegenerative condition associated with apoptosis in the central nervous system comprising administering, intranasally, an effective amount of the Caspase 2 activation inhibitor composition comprising the amino acid sequence AFDAFC to a subject in need thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the neurodegenerative condition associated with apoptosis in the central nervous system, such as Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's chorea, and Creutzfeld-Jacob disease.

### Claim 9 (depends on 8)

The method of claim 8, wherein the Caspase 2 activation inhibitor composition comprising the amino acid sequence AFDAFC is conjugated to a cell-penetrating peptide such as, but not limited to, penetratin1, transportan, pIS1, Tat(48-60), pVEC, MAP, or MTS.
